Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate

European Urology

Volumn 54, Issue 5, 2008, Pages 1066-1072

  Walter, Christian ^a   Al Nawas, Bilal ^a   Grötz, Knut A ^a   Thomas, Christian ^a   Thüroff, Joachim W ^a   Zinser, Viktoria ^a   Gamm, Heinold ^a   Beck, Joachim ^a   Wagner, Wilfried ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bisphosphonate; Bisphosphonate associated osteonecrosis of the jaws; Incidence; Prostate cancer; Risk factor; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DOCETAXEL; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BONE NECROSIS; CLINICAL ARTICLE; DENTURE; GERMANY; HUMAN; INFLAMMATION; MALE; MOUTH HYGIENE; MUCOSAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; TOOTH EXTRACTION;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 55649090798     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.070     Document Type: Article

References (36)

1. Boyle P., Maisonneuve P., and Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46 (1995) 47-55
2. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
3. Bubendorf L., Schopfer A., Wagner U., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31 (2000) 578-583
4. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
5. Goodin S., Rao K.V., and DiPaola R.S. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 7 (2002) 360-370
6. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006250.
7. Di Lorenzo G., Autorino R., Perdonà S., et al. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol 52 (2007) 1020-1027
8. Sciarra A., and Salciccia S. New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?. Eur Urol 52 (2007) 945-947
9. Amin D., Cornell S.A., Gustafson S.K., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33 (1992) 1657-1663
10. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
11. Hikosaka A., Futakuchi M., Ogiso T., Suzuki S., Kohri K., and Shirai T. Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer. Eur Urol 49 (2006) 176-182
12. Saad F., Clarke N., and Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 49 (2006) 429-440
13. Lein M., Wirth M., Miller K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52 (2007) 1381-1387
14. Diel I.J., Bergner R., and Grötz K.A. Bisphosphonate und ihre häufigsten Nebenwirkungen. Journal Onkologie (2005) 6-12
15. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
16. Walter C., Al-Nawas B., Grötz K.A., Kunkel M., and Wagner W. Osteonecrosis of the jaws following treatment with bisphosphonates-own study. Czas Stomatol 6 (2007) 398-404
17. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61 (2003) 1238-1239
18. Grötz K.A., Walter C., Kuttner C., and Al-Nawas B. Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases. Strahlenther Onkol 183 (2007) 190-194
19. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
20. Walter C., Grotz K.A., Kunkel M., and Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15 (2007) 197-202
21. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 (2000) 613-620
22. Rogers M.J., Watts D.J., and Russell R.G. Overview of bisphosphonates. Cancer 80 (1997) 1652-1660
23. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
24. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59 (2001) 193-202
25. Ruggiero S.L., and Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86 (2007) 1013-1021
26. Grötz K.A., and Kreusch T. Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation. DZZ 60 (2006) 10
27. Saarland Ministerium für Justiz GuS. 40 jahre epidemiologisches Krebsregister Saarland 1967-2007: dokumentieren, informieren, evaluieren. 2007.
28. Wang E.P., Kaban L.B., Strewler G.J., Raje N., and Troulis M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65 (2007) 1328-1331
29. Boonyapakorn T., Schirmer I., Reichart P.A., Sturm I., and Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 (2008) 857-869
30. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
31. Von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., and Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147 (2007) 573-577
32. Talamo G., Angtuaco E., Walker R.C., et al. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol 23 (2005) 5217-5223
33. Garcia Saenz J.A., Lopez Tarruella S., Garcia Paredes B., Rodriguez Lajusticia L., Villalobos L., and Diaz Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Patol Oral Cir Bucal 12 (2007) E351-E356
34. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968-971
35. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
36. Zervas K., Verrou E., Teleioudis Z., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134 (2006) 620-623